Cantor Fitzgerald notes that Aravive will report topline results for its Phase 3 AXLerateOC trial of batiraxcept plus paclitaxel in platinum resistant ovarian cancer, or PROC, patients likely in August and argues that “this important potential catalyst for the stock is not getting enough attention.” The firm, which thinks that the risk reward into this readout is positive and that peak sales potential for lead product candidate batiraxcept “remains underappreciated,” keeps an Overweight rating and $18 price target on Aravive shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARAV:
- Aravive files $250M mixed securities shelf
- Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)
- Aravive To Participate in the Jefferies Global Healthcare Conference
- Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
- Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset Batiraxcept